0001567619-18-003758.txt : 20181005 0001567619-18-003758.hdr.sgml : 20181005 20181005164225 ACCESSION NUMBER: 0001567619-18-003758 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181003 FILED AS OF DATE: 20181005 DATE AS OF CHANGE: 20181005 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bilenker Joshua H. CENTRAL INDEX KEY: 0001612312 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36562 FILM NUMBER: 181110973 MAIL ADDRESS: STREET 1: C/O LOXO ONCOLOGY, INC. STREET 2: ONE LANDMARK SQUARE, SUITE 1122 CITY: STAMFORD STATE: CT ZIP: 06901 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Loxo Oncology, Inc. CENTRAL INDEX KEY: 0001581720 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462996673 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 281 TRESSER BOULEVARD, 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06901 BUSINESS PHONE: 203-653-3880 MAIL ADDRESS: STREET 1: 281 TRESSER BOULEVARD, 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06901 4 1 doc1.xml FORM 4 X0306 4 2018-10-03 0 0001581720 Loxo Oncology, Inc. LOXO 0001612312 Bilenker Joshua H. C/O LOXO ONCOLOGY, INC. ONE LANDMARK SQUARE, SUITE 1122 STAMFORD CT 06901 1 1 0 0 President & CEO Common Stock 2001-10-03 4 M 0 10000 3.648 A 145407 D Common Stock 2001-10-03 4 S 0 2905 165.0058 D 142502 D Common Stock 2018-10-03 4 S 0 1225 165.9477 D 141277 D Common Stock 2018-10-03 4 S 0 673 167.0908 D 140604 D Common Stock 2018-10-03 4 S 0 1297 168.2902 D 139307 D Common Stock 2018-10-03 4 S 0 3705 169.0030 D 135602 D Common Stock 2018-10-03 4 S 0 195 169.6779 D 135407 D Common Stock 2018-10-04 4 M 0 10000 3.648 A 145407 D Common Stock 2018-10-04 4 S 0 1700 160.6138 D 143707 D Common Stock 2018-10-04 4 S 0 1553 161.4096 D 142154 D Common Stock 2018-10-04 4 S 0 3152 162.6041 D 139002 D Common Stock 2018-10-04 4 S 0 2000 163.6428 D 137002 D Common Stock 2018-10-04 4 S 0 1395 164.5921 D 135607 D Common Stock 2018-10-04 4 S 0 200 165.5689 D 135407 D Common Stock 30000 I By Joshua H. Bilenker, ttee Joshua Bilenker 2018 GRAT, dated 06/20/2018 Employee Stock Option (Right to Buy) 3.648 2018-10-03 4 M 0 10000 0 D 2024-06-18 Common Stock 10000 82985 D Employee Stock Option (Right to Buy) 3.648 2018-10-04 4 M 0 10000 0 D 2024-06-18 Common Stock 10000 72985 D The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Represents the aggregate of sales effected on the same day at different prices. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.50 to $165.49 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.54 to $166.39 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.54 to $167.47 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.60 to $168.58 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.60 to $169.41 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $169.60 to $169.76 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.11 to $161.10 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $161.11 to $161.97 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $162.13 to $163.11 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.19 to $164.16 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.29 to $165.00 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.45 to $165.66 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The stock option vests and becomes exercisable in 48 equal monthly installments beginning on the vesting commencement date, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. /s/Jennifer Burstein, by power of attorney 2018-10-05